|
Active substance |
erenumab |
|
Holder |
Novartis Pharma |
|
Status |
Closed |
|
Indication |
Treatment of patients diagnosed with migraine, who are in need of prophylactic treatment and for whom no acceptable alternative prophylactic treatment is available |
|
Public documents |
|
|
Last update |
03/06/2020 |
Aimovig®
Last updated on 10/09/2024